Filtered By:
Specialty: General Medicine
Vaccination: Vaccines
This page shows you your search results in order of date.
Order by Relevance | Date
Total 2867 results found since Jan 2013.
Clinical Utility of Sero-Immunological Responses Against SARS-CoV-2 Nucleocapsid Protein During Subsequent Prevalence of Wild-Type, Delta Variant, and Omicron Variant
In conclusion, nucleocapsid antibody provides instructive clues about the immunogenicity of nucleocapsid proteins by different seroconversion rates and titers according to the severity of infection, host immune status, and different variants of concern.PMID:37724496 | DOI:10.3346/jkms.2023.38.e292
Source: J Korean Med Sci - September 19, 2023 Category: General Medicine Authors: Beomki Lee Jae-Hoon Ko Jin Yang Baek Haein Kim Kyungmin Huh Sun Young Cho Cheol-In Kang Doo Ryeon Chung Kyong Ran Peck Eun-Suk Kang Source Type: research
Association between post-COVID-19 status and perioperative morbidity and mortality: protocol for an ambispective cohort study
This study aims to explore the association between time to surgery after COVID-19 diagnosis and the risk of postoperative morbidity and mortality.
Methods and analysis
This is a single-centre ambispective cohort study. Patients with preoperative SARS-CoV-2 infection who require inpatient surgical intervention from 1 December 2022 to 28 February 2023 will be included. Baseline assessment will include the time interval between preoperative SARS-CoV-2 infection and surgery, COVID-19 diagnosis and symptoms, vaccination status and routine preoperative evaluations. The primary outcome will be postoperative composite complicatio...
Source: BMJ Open - September 14, 2023 Category: General Medicine Authors: Che, L., Yu, J., Bai, X., Wang, Y., Zhang, Y., Xu, L., Shen, L., Huang, Y. Tags: Open access, Anaesthesia, COVID-19 Source Type: research
Humoral Response of Different Types of SARS-CoV-2 Vaccines in Patients with Autoimmune Rheumatic Diseases: Experiences from a Serbian Cohort
CONCLUSIONS: In ARDs patients, the highest level of serum IgG antibody against S1/S2 proteins was achieved with the mRNA vaccine, irrespective of the therapy applied or the type of the disease. We recommend a booster dose with mRNA vaccine in all ARDs for the highest SARS-CoV-2 protection without serious post-vaccinal reactions observed.PMID:37698308
Source: The Israel Medical Association Journal - September 12, 2023 Category: General Medicine Authors: Ljudmila Stojanovich Natasa Stanisavljevic Aleksandra Djokovic Milomir Milanovic Jovica Saponjski Yehuda Shoenfeld Source Type: research
Sinopharm (HB02)-associated vaccine-induced immune thrombotic thrombocytopenia: a case report
ConclusionThis case highlights the possibility of vaccine-induced thrombotic thrombocytopenia occurrence by whole-virus coronavirus disease 2019 vaccines. Compared with vector-based vaccines, this phenomenon is rare for whole-virus vaccines. More studies on this type of vaccine regarding thrombotic thrombocytopenia should be considered.
Source: Journal of Medical Case Reports - September 8, 2023 Category: General Medicine Source Type: research
Relapse of immune thrombocytopenia after receiving AstraZeneca coronavirus disease ‐2019 vaccine: A case report
Relapse of immune thrombocytopenia after receiving AstraZeneca coronavirus disease-2019 vaccine: A case report. Key Clinical MessageImmune thrombocytopenic purpura (ITP) is an autoimmune disease characterized by a low platelets count. In this paper, we present a case of ITP relapse in a 31-year-old Iranian woman as a potential complication of the AstraZeneca vaccine.
Source: Clinical Case Reports - September 5, 2023 Category: General Medicine Authors: Saba Seyedi,
Shadan Navid,
Zahra Saadatian Tags: CASE REPORT Source Type: research
Antiviral therapy of coronavirus disease 2019 (COVID-19)
J Formos Med Assoc. 2023 Sep 2:S0929-6646(23)00342-X. doi: 10.1016/j.jfma.2023.08.029. Online ahead of print.ABSTRACTThe coronavirus disease 2019 (COVID-19) pandemic has reached a turning point. The non-pharmaceutical interventions for preventing COVID-19 are lifting. Vaccination uptake is increasing in general, but this strategy is continuously challenged by the rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Of note, the Omicron subvariants spread globally for at least one year, and the most recently developed subvariants show strong immune evasion to preexisting immunity, either from pre...
Source: J Formos Med Assoc - September 4, 2023 Category: General Medicine Authors: Pao-Yu Chen Jann-Tay Wang Shan-Chwen Chang Source Type: research
Early 3 ‑day course of remdesivir for the prevention of the progression to severe COVID‑19 in the elderly: A single‑centre, real‑life cohort study
Exp Ther Med. 2023 Aug 9;26(4):462. doi: 10.3892/etm.2023.12161. eCollection 2023 Oct.ABSTRACTRemdesivir, a viral RNA polymerase inhibitor, has constituted a key component of therapeutic regimens against the pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Originally approved for administration in hospitalized patients, remdesivir leads to improved outcomes in patients with moderate to severe coronavirus disease 2019 (COVID-19). After proving to be effective in hospitalized patients, its use gained approval in early-stage disease for symptomatic outpatients who are at a high risk of progress...
Source: Experimental and Therapeutic Medicine - September 4, 2023 Category: General Medicine Authors: Vasiliki Epameinondas Georgakopoulou Aikaterini Gkoufa Sotiria Makrodimitri Dimitrios Basoulis Aristeidis Tsakanikas Georgios Karamanakos Elpida Mastrogianni Pantazis M Voutsinas Demetrios A Spandidos Chrysovalantis V Papageorgiou Maria N Gamaletsou Nikol Source Type: research
Antiviral therapy of coronavirus disease 2019 (COVID-19)
J Formos Med Assoc. 2023 Sep 2:S0929-6646(23)00342-X. doi: 10.1016/j.jfma.2023.08.029. Online ahead of print.ABSTRACTThe coronavirus disease 2019 (COVID-19) pandemic has reached a turning point. The non-pharmaceutical interventions for preventing COVID-19 are lifting. Vaccination uptake is increasing in general, but this strategy is continuously challenged by the rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Of note, the Omicron subvariants spread globally for at least one year, and the most recently developed subvariants show strong immune evasion to preexisting immunity, either from pre...
Source: J Formos Med Assoc - September 4, 2023 Category: General Medicine Authors: Pao-Yu Chen Jann-Tay Wang Shan-Chwen Chang Source Type: research
